Cresset Announces Appointment of Rob Scoffin as New CEO
Cresset announced the appointment of Dr Rob Scoffin as Chief Executive Officer of Cresset Group. Rob joins Cresset from CambridgeSoft where, as Vice President of European Operations, he was responsible for significant growth in CambridgeSoft’s European business. Rob replaces Beatrice Leigh, who will now become non-executive Chairman of the Board.
Rob has a D.Phil. in chemistry from Oxford and has recently been instrumental in the development of Electronic Lab Notebook systems which he has deployed at several major pharmaceutical companies. Prior to CambridgeSoft, Rob was CEO (Software) for Amedis and Senior Product Manager at Oxford Molecular.
Most read news
Other news from the department people
These products might interest you

Image Integrity Checker by Cytiva
Image integrity checker software - authenticate your images for publication
Safeguard and verify your image data with our free software

Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management

ERP-Software GUS-OS Suite by GUS
Holistic ERP solution for companies in the process industry
Integrate all departments for seamless collaboration

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Researchers Identify Genetic Mutation That May Alter Patients' Response to Cancer Therapeutics - Recurring mutation found in breast, colorectal and ovarian cancers

New Class of Antibiotics to Fight Resistant Bacteria - Development of a highly effective class of antibiotics that fight Gram-negative bacteria in a novel way
